Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 325Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Heartgard

PharmaCompass

01

Brand Name : Heartgard

Ivermectin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 372

2019 Revenue in Millions : 379

Growth (%) : -2

blank

02

Brand Name : Heartgard

Ivermectin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 338

2020 Revenue in Millions : 372

Growth (%) : -2

blank

03

Brand Name : Heartgard

Ivermectin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 350

2021 Revenue in Millions : 338

Growth (%) : 4

blank

04

Brand Name : Heartgard

Ivermectin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 328

2022 Revenue in Millions : 350

Growth (%) : -5

blank

05

Brand Name : Heartgard

Ivermectin/Pyrantel

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin/Pyrantel

Main Therapeutic Indication : Parasitic Infections

Currency : USD

2018 Revenue in Millions : 338

2017 Revenue in Millions : 321

Growth (%) : 5%

blank

06

Brand Name : Heartgard

Ivermectin

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Heartgard

arrow
2024 ACI Convention
Not Confirmed

Ivermectin

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2019 Revenue in Millions : 347

2018 Revenue in Millions : 326

Growth (%) : 6

blank